Function
Is the primary target of the first-line antitubercular drug isoniazid (INH) and of the second-line drug ethionamide (ETH). Overexpressed inhA confers INH and ETH resistance to M.tuberculosis. The mechanism of isoniazid action against InhA is covalent attachment of the activated form of the drug to the nicotinamide ring of NAD and binding of the INH-NAD adduct to the active site of InhA.
Biological Context
Pathway: Lipid metabolism; mycolic acid biosynthesis
Product Specifications
Recombinant Mycobacterium tuberculosis Enoyl-[acyl-carrier-protein] reductase [NADH] (inhA) is a recombinant protein from Mycobacterium tuberculosis (strain CDC 1551 / Oshkosh), expressed in E.coli, covering amino acids 1-269aa, with N-terminal 6xHis-SUMO-tagged tag, molecular weight 44.5kDa, purity Greater than 90% as determined by SDS-PAGE.. Suitable for ELISA and Western Blot applications. Explore more Enzyme proteins →
![Recombinant Mycobacterium tuberculosis Enoyl-[acyl-carrier-protein] reductase [NADH] (inhA), Mycobacterium tuberculosis (strain CDC 1551 / Oshkosh), E.coli, N-terminal 6xHis-SUMO-tagged, 44.5kDa, purity >90% as determined by SDS-PAGE.](https://www.biocrestsci.com/wp-content/uploads/protein/1/BCRECP-003176_SDS.jpg)